Dosing strategies for gene therapies

The original goal of gene therapy was to deliver a single administration that would maintain therapeutic effectiveness over a patient’s lifetime. This ‘one and done’ model appears to have worked for some gene therapies, with promising follow-up data evidenced. However, in some instances, including gene therapies for hemophilia, a single dose may not be enough, and redosing may be required.

At Parexel Biotech, we leverage patient insights and innovations to help gene therapy pioneers understand options for ‘one-and-done’ and redosing gene therapies. The benefit to patients is too great to waste a single moment.

In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline considerations for ’one-and-done’ versus redosing therapies.

Previous Video
Payer insights for cell and gene therapies
Payer insights for cell and gene therapies

It is essential to address the payer landscape very early in development for a product administered once wi...

Next Video
CAR-T: A patient’s cell therapy success story
CAR-T: A patient’s cell therapy success story

Clinical trials of (CAR) T-cell therapies can present unprecedented enrolment challenges. How can we encour...

×

Let's start a conversation...

First Name
Last Name
Job Title
Company Name
Country
Therapeutic Area Interest - optional
Tell us how we can help
Thank you! We'll be in touch soon.
Error - something went wrong!